Adamantiades-Behçet’s Disease

  • C. C. Zouboulis


Adamantiades-Behçet’s disease is a relapsing-remitting multisystemic inflammatory disorder of unknown etiology, classified as systemic vasculitis and characterised by oral and genital ulcers, cutaneous lesions and uveitis. It is distributed world-wide. However, it occurs endemically in the Eastern Mediterranean and in Middle and Far Eastern countries and is rare among inhabitants of Northern European countries, in Central and Southern Africa, in the Americas and in Australia. The highest prevalence has been reported in Turkey (Anatolia, 370:100 000), in Iran (100:100 000) and in Japan (13.5:100 000).


Behçet’s disease Behçet’s syndrome 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aktulga A, Altac M, Muftuoglu AU, Ozyazgan Y, Pazarli H (1980) A double blind study of colchicine in Behçet’s disease. Haematologica 65: 399–402PubMedGoogle Scholar
  2. 2.
    Bradbury AW, Milne AA, Murie JA (1994) Surgical aspects of Behçet’s disease. Br J Surgery 81: 1712–1721CrossRefGoogle Scholar
  3. 3.
    Calgüneri M, Ertenli I, Kiraz S, Erman M, Çelik I (1996) Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet’s disease. Dermatology 192: 125–128PubMedCrossRefGoogle Scholar
  4. 4.
    Calgüneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Çelik I (1996) The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet’s disease. A randomized clinical trial. Arthritis Rheum 39: 2062–2065PubMedCrossRefGoogle Scholar
  5. 5.
    Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tüzün Y, Senocak M, Yazici H (1997) Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum 40: 769–774PubMedCrossRefGoogle Scholar
  6. 6.
    Hashimoto T, Takeuchi A (1992) Treatment of Behçet’s disease. Curr Opin Rheumatol 4: 31–34PubMedGoogle Scholar
  7. 7.
    Huong Du LT, Fain 0, Wechsler B, Cochereau I, Le Hoang P, Souillem J, Piette JC, Blétry O, Godeau P (1990) Intérêt des “bolus” de cyclophosphamide dans la maladie de Behçet. Presse Méd 19: 1355–1358Google Scholar
  8. 8.
    Jorizzo JL, Schmalstieg FC, Solomon AR Jr, Cavallo T Taylor RS III, Rudloff HB, Schmalstieg EJ, Daniels JC (1986) Thalidomide effects in Behçet’s syndrome and pustular vasculitis. Arch Intern Med 146: 878–881PubMedCrossRefGoogle Scholar
  9. 9.
    Jorizzo JL, White WL, Wise CM, Zanolli MD, Sherertz EF (1991) Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteriitis nodosa and Behçet’s disease. J Am Acad Dermatol 24: 973–978PubMedCrossRefGoogle Scholar
  10. 10.
    Masuda K, Nakajima A, Urayama A, Nakae E, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1: 1093–1096PubMedCrossRefGoogle Scholar
  11. 11.
    Nussenblatt RB, Whitcup SM, de Smet MD, Caspi RR, Kozhich AT, Weiner HL, Vistica B, Gery I (1996) Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann N Y Acad Sci 778: 325–337PubMedCrossRefGoogle Scholar
  12. 12.
    Nussenblatt RB (1988) The use of cyclosporin in ocular inflammatory disorder. Transplant Proc 20 (suppl 4): 114–121PubMedGoogle Scholar
  13. 13.
    O’Duffy JD, Robertson DM, Goldstein NP (1984) Chlorambucil in the treatment of uveitis and meningoengephalitis of Behçet’s disease. Am J Med 76: 75–84PubMedCrossRefGoogle Scholar
  14. 14.
    Oyama N, Inoue M, Matsui T, Nuhei Y, Nishibu A, Kaneko F (1997) Minocycline effects on the clinical symptoms in correlation with cytokines produced by peripheral blood mononuclear cells stimulated with streptococcal antigens in Behçet’s disease. In: Hamza M (ed) Behçet’s Disease. Pub Adhoua, Tunis, pp 481–486Google Scholar
  15. 15.
    Ozyazgan Y, Yurdakul S, Yazici H, Tüzün B, Isçimen A, Tüzün Y, Aktunç T, Pazarli H, Hamuryudan V, Müftüoglu A (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol 76: 241–243PubMedCrossRefGoogle Scholar
  16. 16.
    Revuz J, Guillaume JC, Janier M, Hans P, Marchand C, Souteyrand P, Bonnetblanc JM, Claudy A, Dallac S, Klene C et al. (1990) Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 126: 923–927PubMedCrossRefGoogle Scholar
  17. 17.
    Sakane T, Mochizuki M, Inaba G, Masuda K (1995) A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behcet’s disease and allied conditions. Ryumachi 35: 802–813PubMedGoogle Scholar
  18. 18.
    Samangooci SH, Mehryar M, Hakim SM, Safamanesk S (1997) Clinical trial of sulfasalazine for treatment of uveitis Behçet’s disease. In: Hamza M (ed) Behçet’s Disease. Pub Adhoua, Tunis, pp 466–470Google Scholar
  19. 19.
    Simsek H, Dundar S, Telatar H ( 1991 Treatment of Behçet’s disease with indomethacin. Int J Dermatol 30: 54–57PubMedCrossRefGoogle Scholar
  20. 20.
    Tanaka C, Matsuda T, Yukinari Y, Yamada H, Ichikawa Y, Sakane T, Mizushima Y (1997) The beneficial effect of rebamipide on recurrent aphthous ulcers in Behçet’s disease. In: Hamza M (ed) Behçet’s Disease. Pub Adhoua, Tunis, pp 477–480Google Scholar
  21. 21.
    Whitcup SM, Salvo EC Jr, Nussenblatt RB (1994) Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet’s disease. Am J Ophthalmol 118: 39–45PubMedGoogle Scholar
  22. 22.
    Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A (1996) Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med 124: 891–893PubMedCrossRefGoogle Scholar
  23. 23.
    Lotti T, Matucci-Cerinic M. Certaneous fibrikolytic potential, EPA-defendent, is reduced in Behçet’s disease (1989) - Br J Dermatol 121: 713–716Google Scholar
  24. 24.
    Yazici H, Barnes CG. Practical treatment recommendations for pharmacotherapy of Behçet’s syndrome. Drugs 42: 796–804Google Scholar
  25. 25.
    Yazici H, Pazarli H, Barnes CG, Tüzün Y, Özyagzan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE, Yazici B, Somani S, Müftüoglu A (1990) A controlled trial of azathioprin in Behçet’s syndrome. N Engl J Med 322: 281–285PubMedCrossRefGoogle Scholar
  26. 26.
    Zouboulis ChC, Orfanos CE (1997) Systemic interferon-alpha in the treatment of AdamantiadesBehçet’s disease - A review. In: Hamza M (ed) Behçet’s Disease. Pub Adhoua, Tunis, pp 441–446Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • C. C. Zouboulis

There are no affiliations available

Personalised recommendations